Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) issued its earnings results on Monday. The biotechnology company reported ($0.12) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.03, Bloomberg Earnings reports.

Shares of Bellerophon Therapeutics (NASDAQ:BLPH) traded up 0.84% during midday trading on Tuesday, hitting $1.20. 34,804 shares of the stock were exchanged. Bellerophon Therapeutics has a 12-month low of $0.43 and a 12-month high of $1.98. The firm has a 50-day moving average price of $1.39 and a 200 day moving average price of $1.29. The firm’s market cap is $39.59 million.

BLPH has been the subject of a number of recent research reports. Ladenburg Thalmann Financial Services initiated coverage on shares of Bellerophon Therapeutics in a research report on Monday, April 17th. They issued a “buy” rating and a $4.50 target price for the company. Zacks Investment Research upgraded shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research report on Tuesday, July 11th. Finally, ValuEngine cut shares of Bellerophon Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 10th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $3.67.

TRADEMARK VIOLATION WARNING: “Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Releases Earnings Results, Beats Expectations By $0.03 EPS” was first reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Earnings History for Bellerophon Therapeutics (NASDAQ:BLPH)

Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with's FREE daily email newsletter.